Abeona Therapeutics IncのSMA 200
Abeona Therapeutics IncのSMA 200は何ですか。
Abeona Therapeutics IncのSMA 200は$6 +0.08%です。
SMA 200の定義は何ですか。
SMA 200は、過去200日間の終値の非加重平均として計算された過去200日間の平均株価です。
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
NASDAQのセクタHealth CareにおけるSMA 200の企業と比べるAbeona Therapeutics Inc
Abeona Therapeutics Incは何をしますか。
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Abeona Therapeutics Incと類似のsma 200
- Applied Dna Sciences IncのSMA 200は$6 -269.28%です。
- Voya International High Dividend Equity Income FundのSMA 200は$6 +0.00%です。
- MDC PartnersのSMA 200は$6 -2.95%です。
- RiskifiedのSMA 200は$6 -21.88%です。
- Ferratum OyjのSMA 200は€6 -12.67%です。
- Zevra Therapeutics IncのSMA 200は$6 +3.90%です。
- Abeona Therapeutics IncのSMA 200は$6 +0.08%です。
- Biodelivery Sciences InternationalのSMA 200は$6 +0.00%です。
- Antares Pharma IncのSMA 200は$6 +0.00%です。
- ChesswoodのSMA 200はCAD$6 -521.14%です。
- Lantern PharmaのSMA 200は$6 -50.31%です。
- Nuveen Credit Strategies Income FundのSMA 200は$6 +5.37%です。
- IMP PowersのSMA 200は₨6 +0.00%です。